MAGED2

Across TCGA pan-cancer cohorts, MAGED2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of MAGED2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where MAGED2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAGED2 is over-expressed in tumor, although a few such as THCA and UCEC show the opposite, repressed pattern.

COAD, LIHC, and THCA are the cancer types where MAGED2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAGED2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	All	+0.874	<.001	11	view →
LIHC	Female	II,III,IV	+1.944	<.001	9	view →
THCA	Male	IV	−1.036	<.001	9	view →
BRCA	All	III,IV	+1.524	<.001	8	view →
UCEC	All	All	−0.804	<.001	6	view →
KICH	All	All	−0.584	.001	6	view →
CHOL	Male	All	+2.069	<.001	5	view →
BLCA	Male	III,IV	−1.167	<.001	5	view →
LUSC	Female	II,III,IV	−0.624	.007	5	view →
KIRP	Male	All	−0.508	<.001	2	view →
HNSC	All	III,IV	+0.488	.012	2	view →
LUAD	All	All	+0.259	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

MAGED2–COAD

Open the COAD breakdown →